ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Precision BioSciences Inc

Precision BioSciences Inc (DTIL)

10.24
0.11
(1.09%)
Closed July 15 4:00PM
10.24
0.00
( 0.00% )
Pre Market: 4:00AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
10.24
Bid
9.80
Ask
10.35
Volume
-
0.00 Day's Range 0.00
8.25 52 Week Range 21.30
Market Cap
Previous Close
10.24
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
40,282
Shares Outstanding
6,925,598
Dividend Yield
-
PE Ratio
-1.16
Earnings Per Share (EPS)
-8.85
Revenue
48.73M
Net Profit
-61.32M

About Precision BioSciences Inc

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segment... Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food out of which the Therapeutics segment act as a key revenue driver for the firm. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Precision BioSciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker DTIL. The last closing price for Precision BioSciences was $10.24. Over the last year, Precision BioSciences shares have traded in a share price range of $ 8.25 to $ 21.30.

Precision BioSciences currently has 6,925,598 shares outstanding. The market capitalization of Precision BioSciences is $70.92 million. Precision BioSciences has a price to earnings ratio (PE ratio) of -1.16.

DTIL Latest News

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the...

Precision BioSciences Announces its Addition to the Russell Microcap® Index

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene...

Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene...

Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.0411.30434782619.210.389.11308949.91001191CS
4-0.52-4.8327137546510.7611.029.1452129.63040024CS
120.575.894519131339.6713.4369.14028210.90043577CS
26-2.777-21.333640623813.01719.42999.124005511.80443501CS
52-10.445-50.495528160520.68521.38.2577386212.76749825CS
156-313.76-96.8395061728324431.48.2588560659.02711764CS
260-409.76-97.5619047619420710.1068.25815640142.07697184CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CDTConduit Pharmaceuticals Inc
$ 0.4486
(86.92%)
20.37M
WNWMeiwu Technology Company Ltd
$ 1.23
(38.20%)
2.22M
SYRASyra Health Corporation
$ 1.75
(31.09%)
1
WLDSWearable Devices Ltd
$ 0.532
(23.32%)
412.57k
WINTWindtree Therapeutics Inc
$ 4.50
(21.62%)
10
GRNQGreenpro Capital Corporation
$ 0.9665
(-18.09%)
80.61k
AMIXAutonomix Medical Inc
$ 1.14
(-17.39%)
419.04k
AREBAmerican Rebel Holdings Inc
$ 0.561
(-16.64%)
143.83k
CYNCYNGN Inc
$ 7.82
(-14.81%)
12.26k
MFImF International Ltd
$ 0.80
(-14.44%)
3.1k
CDTConduit Pharmaceuticals Inc
$ 0.4573
(90.54%)
20.32M
KRKR36Kr Holdings Inc
$ 0.3125
(5.15%)
4.57M
SLNASelina Hospitality PLC
$ 0.0662
(5.75%)
2.45M
WNWMeiwu Technology Company Ltd
$ 1.23
(38.20%)
2.22M
MAXNMaxeon Solar Technologies Ltd
$ 0.2211
(-2.60%)
1.46M

DTIL Discussion

View Posts
Monksdream Monksdream 2 weeks ago
DTIL under $10
👍️0
jondoeuk jondoeuk 1 month ago
I think they did, but there are still a lot of vampires sucking away at the (limited) revenue.
👍️0
Monksdream Monksdream 3 months ago
DTIL under $10
👍️0
NY1972 NY1972 3 months ago
Why they hired a Chief People Officer instead of of trimming head count? another GNCA IMO
👍️0
jondoeuk jondoeuk 3 months ago
Management can try and spin this as much as they want, but this is a failure https://www.businesswire.com/news/home/20240416117356/en/Precision-BioSciences-Announces-Return-of-Programs-and-Conclusion-of-Collaboration-with-Prevail-Therapeutics
👍️0
jondoeuk jondoeuk 3 months ago
If one of the companies that are developing off-the-shelf succeed, I don't see why any insurer will pay the price tag of an autologous therapy (assuming similar data/success). On paper, it should be easier than oncology.
👍️0
Monksdream Monksdream 4 months ago
DTIL 10Q due March 13
👍️0
jondoeuk jondoeuk 4 months ago
That didn't take long! https://www.businesswire.com/news/home/20240301968620/en/Precision-BioSciences-Announces-40.0-Million-Offering-of-Common-Stock-and-Warrants

Maybe things are going slower on the clinical front or no milestone payments are expected.
👍️0
rtrstock rtrstock 5 months ago
What do you mean an offering?
👍️0
surf1944 surf1944 5 months ago
Precision BioSciences, Inc. (DTIL) will effect a one-for-thirty (1-30) reverse split of its Common Stock. The reverse stock split will become effective on Wednesday, February 14, 2024. In conjunction with the reverse split, the CUSIP number will change to 74019P207

The 1 for 30 R/S will make it easy is come out with an offering in the next week or so.
👍️0
rtrstock rtrstock 5 months ago
1 for 30 not bad, but still will have to hold a long time to get my money back, if I ever do, averaged in at maybe 1.30, so uncertain what price will need to be after reverse split eventually to even break even. Wanting to hold long and make money eventually, but unsure if that's still possible.

I have 5100 shares, so that will be cut to practically nothing, it'd have to go to nearly 50.00 a share for me to make my money back?

Is this correct? Is basically everyone even the big investors like Lilly and Cargill losing big on this one?
👍️0
jondoeuk jondoeuk 5 months ago
Now there will be one. The BOD approved a 1-for-30 R/S. It will become effective at 5:00 p.m. ET on Feb 13. The uncertainty has been eliminated.
👍️0
rtrstock rtrstock 6 months ago
Guess I'll hold even if there is a R/S
👍️0
jondoeuk jondoeuk 6 months ago
I thought they would, but it seems to me that they want to allow the clock to run before they set a R/S. Looking at the filing, it leaves the effective date to the BOD's discretion. It also gives the them the discretion to abandon it. The company has until the 22nd of April for the stock price to attain what is needed, thereby keeping its listing.
👍️0
NY1972 NY1972 6 months ago
Side dish becomes the main course. High paid bio CEOs need another bait and switch.
👍️0
jondoeuk jondoeuk 6 months ago
Autoimmune diseases are clearly the next frontier for CAR-T/NK cell therapies, with numerous biotech and (big) pharma companies in the space https://finance.yahoo.com/news/precision-biosciences-completes-license-deal-120000510.html
👍️0
81vette 81vette 6 months ago
Res. Breakout,after hours could get fun
👍️ 1
81vette 81vette 6 months ago
Accumulation at nhod
👍️ 1
81vette 81vette 6 months ago
11th most newly watched ticker,do dd,others are
👍️0
81vette 81vette 6 months ago
The 2.5m buy, should open some eyes
👍️0
81vette 81vette 6 months ago
Death hour is over,mid day vol surge coming,this pennant has gotten pointy/pokey/stabby(technical terms lol)held strong with .4333 last low bounce,demand growing now,waiting for thru .44 to send it higher
👍️0
81vette 81vette 6 months ago
DTIL astronomical potential=greed/hold,tutes own 27%,insiders 21%,100M cash(no offerings),eps this year up 60%/sales past 5years up 102%(tells me sales have started and that explains tutes,I expect they buy more now) 27%below the sma200(so it’s got at least that much run room) target price 2.62, 198 employees,bullish chart since Oct 30th,could be some bashers because it is optionable/shortable,institutional could send this flying up,relative buying vol up 148Xs today ,shares available to short is dropping but still 3.5M(was 4.3m) overall I like that I can put this in my portfolio for long(or until chart breaks) and not have to watch it like a nail biting pump and dump,I have too many of those already lol
👍️0
rtrstock rtrstock 7 months ago
What indication of a RS is there? Or is it assumed?

This looks like a good buy to me, am I wrong?
👍️0
NY1972 NY1972 8 months ago
Plenty dead bios walking in this mkt. still handing out options like clock work.
👍️0
NY1972 NY1972 8 months ago
This bio is walking dead. Failure to let go the PhDs and CARTs a few years ago costed hundreds millions. ARCUS will be bought by IECure after the cash dries up.
👍️0
jondoeuk jondoeuk 8 months ago
Yes, but I think the R/S will happen.
👍️0
Sirpeter Sirpeter 8 months ago
There's still time
👍️0
jondoeuk jondoeuk 8 months ago
So, at 4:30pm the day before Thanksgiving, they announce a special meeting to vote on a R/S. It will take place on Thurs, Jan 18, '24, at 11:00 am, Eastern Time, at a ratio ranging from 1-for-10 and 1-for-30.
👍️0
Sirpeter Sirpeter 8 months ago
Moving up nicely...looks good
👍️0
knrorrel knrorrel 8 months ago
nice chart, bottom now and here, Now get the news out and let's see what happens, maybe we'll almost never see these low prices down here on the ground again.
imho
👍️0
knrorrel knrorrel 8 months ago
News Out, should running hard in good News
imho
👍️0
knrorrel knrorrel 8 months ago
a really nice $DTIL News https://ih.advfn.com/stock-market/NASDAQ/precision-biosciences-DTIL/stock-news/92484281/precision-biosciences-reports-third-quarter-2023-f


👍️0
rtrstock rtrstock 9 months ago
Well on stock twits they are saying there is no filed reverse split and that they are expecting an extension to be filed, so I hope you are right. I'm uncertain what all is going on, but I like what this company is doing with it's aspirations in medicine, so staying with it. Just accumulated more, lowered my average cost.
👍️0
konshe konshe 9 months ago
bottom rebound coming, time to buy.
👍️ 1
Monksdream Monksdream 9 months ago
DTIL new 52 week low
👍️0
Monksdream Monksdream 10 months ago
DTIL new 52 week low
👍️0
Monksdream Monksdream 10 months ago
DTIL new 52 wewek low
👍️0
NY1972 NY1972 10 months ago
DTIL founders never worried about cash until the meltdown. They hired too many PhDs, built fancy expensive labs with lots of promises. They never tried to trim the expenses to make sure there will be cash left for clinical trials. High burn and lots of GT bios spell doom for this bio.
👍️0
jondoeuk jondoeuk 10 months ago
I should have pointed out that companies are happening to develop small[er] nucleases. Here is one paper from Casebia Therapeutics, which is a joint venture between CRSP and BAYN https://www.nature.com/articles/s41467-021-24454-5

Also, in 2020, researchers led by Dr. Liu created a new base editor that could perform C-to-T conversion of DNA in mitochondria. However, it had limitations, not only being restricted to that conversion, but mostly limited a certain motif. This means that it could correct only 10% of confirmed pathogenic mitochondrial point mutations https://www.nature.com/articles/s41587-022-01256-8

Last year another novel base editor was created that could achieve A-to-G conversion. Being able to perform that could correct 43% of confirmed pathogenic mitochondrial point mutations https://www.cell.com/cell/fulltext/S0092-8674(22)00389-0

However, I don't see either base editor entering the clinic for a number of years.
👍️0
jondoeuk jondoeuk 10 months ago
Or it could end up like TRIL. ARCUS has some benefits over current CRISPR systems, manly its size, can edit the mitochondrial genome and IP is not a mess.
👍️0
NY1972 NY1972 10 months ago
IECure will buy the ARCUS IP when cash is 0 in 18 months.
👍️0
jondoeuk jondoeuk 10 months ago
Not the most productive use of its cash so far. The R&D Day could change that, but the market doesn't seem to think it.
👍️0
NY1972 NY1972 11 months ago
this is a homeless shelter for PhDs. Cash is not spent on patients. They hired a chief people officer to cut the pie.
👍️0
jondoeuk jondoeuk 11 months ago
The market did not find the recent announcement attractive https://www.businesswire.com/news/home/20230815091930/en/Precision-BioSciences-Completes-Strategic-Transaction-with-Imugene-for-Azer-Cel-in-Cancer

I think a reverse split is a possibility, especially after the announcement couldn't move the PPS. If that happens, will likely add fuel to any downward price pressure. Management don't seem the best. Now it's do or die with the in vivo programs.
👍️0
rtrstock rtrstock 11 months ago
That's what I'm afraid of, guess I'll just wait. Keep my shares.
👍️0
J-mak J-mak 11 months ago
In my opinon slim very very slim
👍️0
rtrstock rtrstock 11 months ago
What's the educated guess?

What's realistically possible by October date for pps to be more than $1.00
👍️0
J-mak J-mak 11 months ago
Didn't you already say that
👍️0
Monksdream Monksdream 11 months ago
DTIL new 52 week low
👍️0
rtrstock rtrstock 11 months ago
$227 Million in Upfront Economics and Milestone Payments for Azer-Cel in Addition to Double-Digit Royalties on Sales
Imugene
https://www.businesswire.com/news/home/20230815091930/en/Precision-BioSciences-Completes-Strategic-Transaction-with-Imugene-for-Azer-Cel-in-Cancer
👍️0

Your Recent History

Delayed Upgrade Clock